{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:34:07Z","timestamp":1792622047949,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.07.033","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:28:03Z","timestamp":1659140883000},"page":"5322-5332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Haiping","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2022.07.033_b0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-05258-2","article-title":"An outbreak of acute respiratory infection at a training base in Beijing, China due to human adenovirus type B55","volume":"20","author":"Lu","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.033_b0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.vaccine.2022.07.033_b0015","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.15585\/mmwr.mm7032e3","article-title":"Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged \u226565 Years - COVID-NET, 13 States, February-April 2021","volume":"70","author":"Moline","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.033_b0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.033_b0025","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","article-title":"Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study","volume":"10","author":"Li","year":"2021","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.vaccine.2022.07.033_b0030","article-title":"Antibody and T cell responses to Sinopharm\/BBIBP-CorV in na\u00efve and previously infected individuals in Sri Lanka","author":"Jeewandara","year":"2021","journal-title":"medRxiv"},{"issue":"16","key":"10.1016\/j.vaccine.2022.07.033_b0035","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.vaccine.2022.07.033_b0040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.46234\/ccdcw2022.071","article-title":"COVID-19 Mortality and Vaccine Coverage \u2014 Hong Kong Special Administrative Region, China, January 6, 2022\u2013March 21, 2022","volume":"4","author":"Dallas","year":"2022","journal-title":"China CDC weekly"},{"key":"10.1016\/j.vaccine.2022.07.033_b0045","doi-asserted-by":"crossref","unstructured":"McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong. medRxiv. 2022.","DOI":"10.2139\/ssrn.4064649"},{"issue":"37","key":"10.1016\/j.vaccine.2022.07.033_b0050","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15585\/mmwr.mm6937a6","article-title":"Decreased Influenza Activity During the COVID-19 Pandemic - United States, Australia, Chile, and South Africa, 2020","volume":"69","author":"Olsen","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.07.033_b0055","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"Brueggemann","year":"2021","journal-title":"The Lancet Digital health"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.033_b0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2021.08.013","article-title":"Changes in the pathogenic spectrum of acute respiratory tract infections during the COVID-19 epidemic in Beijing, China: A large-scale active surveillance study","volume":"83","author":"Dong","year":"2021","journal-title":"The Journal of infection"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.033_b0065","article-title":"Etiological and epidemiological features of acute respiratory infections in China","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.07.033_b0070","unstructured":"Gong H, Shen X, Yan H, Lu WY, Zhong GJ, Dong KG, et al. [Estimating the disease burden of seasonal influenza in China, 2006-2019]. Zhonghua yi xue za zhi. 2021;101:560-7."},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.033_b0075","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315","volume":"6","author":"Wahl","year":"2018","journal-title":"The Lancet Global health"},{"issue":"47","key":"10.1016\/j.vaccine.2022.07.033_b0080","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1016\/j.vaccine.2016.10.013","article-title":"Seasonal influenza vaccination in China: Landscape of diverse regional reimbursement policy, and budget impact analysis","volume":"34","author":"Yang","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.033_b0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/21645515.2020.1765620","article-title":"Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups","volume":"17","author":"Liu","year":"2021","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.033_b0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12889-020-8388-3","article-title":"Vaccination coverage with the pneumococcal and influenza vaccine among persons with chronic diseases in Shanghai, China, 2017","volume":"20","author":"Wang","year":"2020","journal-title":"BMC public health"},{"issue":"18","key":"10.1016\/j.vaccine.2022.07.033_b0095","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.vaccine.2016.02.032","article-title":"The free vaccination policy of influenza in Beijing, China: The vaccine coverage and its associated factors","volume":"34","author":"Lv","year":"2016","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.07.033_b0100","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1080\/21645515.2021.1932218","article-title":"Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis","volume":"17","author":"Liang","year":"2021","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.033_b0105","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2105\/AJPH.2011.300512","article-title":"Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers","volume":"102","author":"Gilchrist","year":"2012","journal-title":"Am J Public Health"},{"issue":"34","key":"10.1016\/j.vaccine.2022.07.033_b0110","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1016\/j.vaccine.2020.06.047","article-title":"Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality","volume":"38","author":"Thindwa","year":"2020","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2022.07.033_b0115","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.vaccine.2017.09.012","volume":"35","author":"Ofori-Anyinam","year":"2017","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2022.07.033_b0120","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.vaccine.2021.03.041","article-title":"Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen","volume":"39","author":"Chen","year":"2021","journal-title":"China Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.033_b0125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/vaccines9030212","article-title":"Heightened Willingness toward Pneumococcal Vaccination in the Elderly Population in Shenzhen, China: A Cross-Sectional Study during the COVID-19 Pandemic","volume":"9","author":"Zhang","year":"2021","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.033_b0130","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2020.1871571","article-title":"Impact of the coronavirus disease 2019 epidemic and a free influenza vaccine strategy on the willingness of residents to receive influenza vaccines in Shanghai","volume":"17","author":"Zhou","year":"2021","journal-title":"China Human vaccines & immunotherapeutics"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.033_b0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.033_b0140","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.vaccine.2019.10.021","article-title":"Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults","volume":"38","author":"Essink","year":"2020","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.07.033_b0145","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1080\/21645515.2018.1455476","article-title":"Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial","volume":"14","author":"Nakashima","year":"2018","journal-title":"Human vaccines & immunotherapeutics"},{"key":"10.1016\/j.vaccine.2022.07.033_b0150","series-title":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification","author":"Who","year":"2018"},{"key":"10.1016\/j.vaccine.2022.07.033_b0155","doi-asserted-by":"crossref","unstructured":"Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. The Cochrane database of systematic reviews. 2013;2013:Cd000422.","DOI":"10.1002\/14651858.CD000422.pub3"},{"key":"10.1016\/j.vaccine.2022.07.033_b0160","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1186\/s12889-020-09613-5","article-title":"Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis","volume":"20","author":"Matthews","year":"2020","journal-title":"BMC public health"},{"issue":"9","key":"10.1016\/j.vaccine.2022.07.033_b0165","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1086\/656587","article-title":"Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study","volume":"51","author":"Hung","year":"2010","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.vaccine.2022.07.033_b0170","doi-asserted-by":"crossref","unstructured":"The Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC weekly. 2020;2:113-22.","DOI":"10.46234\/ccdcw2020.032"},{"key":"10.1016\/j.vaccine.2022.07.033_b0175","first-page":"1775","article-title":"Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.vaccine.2022.07.033_b0180","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: Definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:31Z","timestamp":1759403791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22009197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":36,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22009197"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}